Temozolomide + Vorinostat
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia With 11q23-abnormality in Relapse
Conditions
Acute Myeloid Leukemia With 11q23-abnormality in Relapse
Trial Timeline
May 1, 2013 → Nov 17, 2014
NCT ID
NCT01550224About Temozolomide + Vorinostat
Temozolomide + Vorinostat is a phase 2 stage product being developed by Merck for Acute Myeloid Leukemia With 11q23-abnormality in Relapse. The current trial status is completed. This product is registered under clinical trial identifier NCT01550224. Target conditions include Acute Myeloid Leukemia With 11q23-abnormality in Relapse.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia With 11q23-abnormality in Relapse were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01550224 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia With 11q23-abnormality in Relapse